- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05884502
A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in Stroke
A Multicenter Prospective Randomized-controlled Interventional Study to Evaluate the Effect of High Dose Rosuvastatin Versus High Dose Rosuvastatin and Ezetimibe in Acute Ischemic Stroke Patients
High-intensity statins are recommended for secondary prevention of stroke in patients with atherosclerotic ischemic stroke. According to the guidelines of the American Heart Association and the American Stroke Society, high-intensity or high-dose statins are recommended for high-risk groups of atherosclerotic cardiovascular disease (ASCVD). Statin therapy is recommended even if it is less than 100 mg/dL. The 2016 ESC/EAS and 2017 AACE guidelines include ischemic stroke and transient cerebral ischemic attacks caused by atherosclerosis in ASCVD, classifying them as ultra-high-risk groups, and recommending LDL cholesterol of less than 70 mg/dL as a treatment goal. The recently published guidelines for dyslipidemia in Korea also recommend that the target level of LDL cholesterol in patients with atherosclerotic ischemic stroke and transient ischemic attack be reduced to less than 70 mg/dL or 50% or more from the baseline.
According to a previous study on the efficacy and safety of high-intensity rosuvastatin in patients with ischemic stroke, it is not clear whether the use of rosuvastatin 20 mg prevents recurrence of cerebral infarction in the acute stage, but it is safe and effective for hemorrhagic conversion of cerebral infarction. In addition, the results were shown when rosuvastatin and ezetimibe were combined in patients with high cardiovascular risk, LDL cholesterol and total cholesterol decreased more in the combined group than in the single agent group. In a study comparing the group whose LDL cholesterol target was reduced to 70 mg/dL or less after stroke and the group maintained at 90-110 mg/dL, the group whose LDL cholesterol was controlled to 70 mg/dL or less It was confirmed that the incidence of cardiovascular disease was reduced. Existing studies aimed at general high-risk groups, not specific disease groups, and as in this study, studies were not conducted on a single disease group called acute stroke. In addition, there are only limited studies on the effectiveness and safety of diseases that occur mainly in the elderly, such as acute stroke. Therefore, there are currently no studies on the clinical efficacy and safety of high-intensity rosuvastatin and ezetimibe combination therapy for patients with acute cerebral infarction.
Study Overview
Status
Conditions
Detailed Description
Multicenter, randomized controlled trial to compare the efficacy and safety of the test group (high-dose rosuvastatin and ezetimibe combined administration group) and control group (high-dose rosuvastatin single administration group) to achieve the target LDL-C level in patients who have recently experienced an ischemic stroke; It is an open-label, investigator-led clinical trial.
In this clinical trial, treatment is performed according to the general treatment procedure for patients who have recently had an ischemic stroke. Subjects who agree to participate in the clinical trial and satisfy the selection and exclusion criteria are the test group (combination of high-dose rosuvastatin and ezetimibe). Administration group) and control group (high-dose rosuvastatin single administration group) are randomly assigned in a 1:1 ratio.
Clinical investigational drugs according to randomization are administered to hospitalized patients, and when discharged, they are allowed to take the provided clinical investigational drugs for a total of 90 days. After the baseline, on the 7th day or at discharge (1st follow-up), and on the 30th day (2nd follow-up), compliance with medication and occurrence of adverse reactions are observed, and on the 90th day (3rd follow-up), lipid concentration test is performed. Check LDL-C levels and compare with baseline LDL-C levels.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Sungwook Yu, M.D.
- Phone Number: 82-2-920-5510
- Email: song4yu@korea.ac.kr
Study Locations
-
-
-
Seoul, Korea, Republic of, 02841
- Recruiting
- Korea University Anam Hospital
-
Contact:
- Sungwook Yu, M.D.
- Phone Number: 82-2-920-5510
- Email: song4yu@korea.ac.kr
-
Seoul, Korea, Republic of, 08308
- Recruiting
- Koera University Guro Hospital
-
Contact:
- Chi-Kyung Kim, M.D.
- Email: ckkim7@gmail.com
-
-
Gyeonggi-do
-
Ansan, Gyeonggi-do, Korea, Republic of, 15355
- Recruiting
- Korea University Ansan Hospital
-
Contact:
- Jin-Man Jung, M.D.
- Email: sodium75@hanmail.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Those with primary hypercholesterolemia among those whose lesions were confirmed by brain CT or MRI within 48 hours of the onset of ischemic stroke
- Adults 19 years of age or older
- Patients who agreed to participate in this study
Exclusion Criteria:
- Patients scheduled for carotid endarterectomy or stenting, cerebral artery stenting, coronary angioplasty and stenting, or coronary artery bypass surgery within 3 months
- Patients with malignant tumors that have not been cured
- Patients who have participated in other drug clinical trials within the last 30 days
- Patients expected to experience side effects when taking rosuvastatin and ezetimibe
- Patients who did not consent to participate in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination therapy
combination of high-dose rosuvastatin and ezetimibe
|
combination of rosuvastatin 20mg and ezetimibe 10mg
|
Active Comparator: Single therapy
high-dose rosuvastatin single administration group
|
rosuvastatin 20mg monotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute value of LDL-C (low-density lipoprotein cholesterol) reduction
Time Frame: 90 days after enrollment
|
low-density lipoprotein cholesterol reduction at 90 days after enrollment
|
90 days after enrollment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of reaching target LDL-C (low-density lipoprotein cholesterol) levels
Time Frame: 90 days after enrollment
|
LDL-C (low-density lipoprotein cholesterol) < 70 mg/dL or 50% or more decrease from baseline
|
90 days after enrollment
|
Changes in total cholesterol, HDL-C (high-density lipoprotein cholesterol), and TG (Triglyceride) levels at 3 months compared to randomization
Time Frame: 90 days after enrollment
|
Changes in total cholesterol, HDL-C (high-density lipoprotein cholesterol), and TG (Triglyceride) levels at 90 days
|
90 days after enrollment
|
Clinical event occurence- major cardiovascular adverse event (MACE)
Time Frame: 90 days after enrollment
|
MACE; relapse of stroke, cardiovascular death, other death, occurrence of coronary artery disease, occurrence of myocardial infarction requiring percutaneous coronary intervention
|
90 days after enrollment
|
Clinical Stroke Scale
Time Frame: 90 days after enrollment
|
NIHSS (National Institute of Health stroke scale) score,
|
90 days after enrollment
|
Clinical Stroke Scale
Time Frame: 90 days after enrollment
|
mRS (modified Rankins scale) score
|
90 days after enrollment
|
Safety endpoints
Time Frame: 90 days after enrollment
|
newly diagnosed diabetes mellitus
|
90 days after enrollment
|
Safety endpoints
Time Frame: 90 days after enrollment
|
newly developed muscle symptoms measured with statin related muscle symptoms questionnaire (SAMS-Q)
|
90 days after enrollment
|
Safety endpoints
Time Frame: 90 days after enrollment
|
liver enzyme levels (AST in IU/L, ALT in IU/L)
|
90 days after enrollment
|
Safety endpoints
Time Frame: 90 days after enrollment
|
development of intracranial hemorrhage
|
90 days after enrollment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Lipid Metabolism Disorders
- Stroke
- Ischemic Stroke
- Dyslipidemias
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Rosuvastatin Calcium
- Ezetimibe
Other Study ID Numbers
- 2021AN0073
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidemias
-
IlDong Pharmaceutical Co LtdCompletedMixed DyslipidemiasKorea, Republic of
-
Orient Pharma Co., Ltd.CompletedPrimary Hypercholesterolemia | Mixed DyslipidemiasTaiwan, Australia, New Zealand
-
University of PaviaFoundation IRCCS San Matteo HospitalRecruiting
-
Çankırı Karatekin UniversityHacettepe UniversityRecruiting
-
Daewoong Pharmaceutical Co. LTD.RecruitingDyslipidemiasKorea, Republic of
-
AstraZenecaParexelRecruitingDyslipidemiaUnited States, United Kingdom
-
Jiangxi University of Traditional Chinese MedicineNot yet recruiting
-
Mackay Memorial HospitalAmgenRecruiting
-
EMSRecruiting
-
Daiichi SankyoDaiichi Sankyo Korea Co., Ltd.Active, not recruiting
Clinical Trials on combination of high-dose rosuvastatin and ezetimibe
-
Yuhan CorporationCompletedAcute Coronary Syndrome | Carotid Atherosclerotic Plaque With InflammationKorea, Republic of
-
Yonsei UniversityNot yet recruitingPeripheral Artery Disease | Polyvascular DiseaseKorea, Republic of
-
Yonsei UniversityCompletedDyslipidemias | Nonalcoholic Fatty Liver DiseaseKorea, Republic of
-
Laboratorios Silanes S.A. de C.V.Completed
-
Saint Vincent's Hospital, KoreaRecruitingCoronary Artery Disease | Dyslipidemias | Primary PreventionKorea, Republic of
-
Haisco Pharmaceutical Group Co., Ltd.CompletedStudy of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD)HypercholesterolemiaChina
-
Texas A&M UniversityNutraboltCompletedNutritional Supplements
-
Hanmi Pharmaceutical Company LimitedCompletedHealthyKorea, Republic of
-
Collegium Medicum w BydgoszczyCompletedHypercholesterolemiaPoland
-
Kobe UniversityCompletedCoronary Artery Disease Progression